

In the Claims:

1-123. (canceled).

124. (Currently amended) An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:20 shown in Figure 12 (SEQ ID NO:20);
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:20 shown in Figure 12 (SEQ ID NO:20), lacking its associated signal peptide;
- (c) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 12 (SEQ ID NO:20);~~ or
- (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209792;
wherein, the nucleic acid encoding said polypeptide is amplified in lung cell carcinomas
~~tumors~~.

125. (Currently amended) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of SEQ ID NO:20 shown in Figure 12 (SEQ ID NO:20).

126. (Currently amended) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of SEQ ID NO:20 shown in Figure 12 (SEQ ID NO:20), lacking its associated signal peptide.

127-128. Canceled.

129. (Previously presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209792.

130. (Previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 124 fused to a heterologous polypeptide.
131. (Previously presented) The chimeric polypeptide of Claim 130, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.